Solid Biosciences (NASDAQ:SLDB) Bolsa

SOLID BIOSCIENCES INC

Solid Biosciences

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

Solid Biosciences Inc

Polyrizon Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) saw a dip in its stock value during after-hours trading on Wednesday.
What Happened: The after-hours price of Polyrizon&#8217;s stock was $0.92, marking a 12.02% dip from the previous day&#8217;s closing price of $1.04. This follows a regular trading session surge of 52.47%.
See Also: <a href="https://benzinga.com/markets/25/07/46383911/virginia-homeowner-says-neighbor-illegally-cut-down-89-year-old-oak-tree-on-his-land-then-had-the-ne">Virginia Homeowner Says Neighbor Illegally Cut Down 89-Year-Old Oak Tree On His Land — Then Had the Nerve To &#8216;Demand&#8217; He Pay Half The $2k Bill &#8211; Benzinga</a>
The surge in the stock value on Tuesday follows the company&#8217;s successful appeal to the NASDAQ panel, which enabled it to retain its listing on the exchange. The appeal was crucial for the biotech company, as it faced the risk of being delisted due to non-compliance with Nasdaq&#8217;s listing rules.
Why It Matters: Polyrizon&#8217;s stock value has been on a rollercoaster ride recently. Earlier in July, the company&#8217;s stock value also <a href="https://www.benzinga.com/insights/movers/25/07/46425317/12-health-care-stocks-moving-in-tuesdays-intraday-session">experienced a significant increase</a> after the news of its continued Nasdaq listing. This was after a hearing panel confirmed the company&#8217;s compliance with the exchange&#8217;s listing rules.
These developments come on the heels of Polyrizon&#8217;s announcement of <a href="https://www.benzinga.com/news/25/06/45901285/polyrizon-announces-preclinical-results-from-study-evaluating-its-trap-target-platform-showing-formu">successful preclinical results</a> from a study evaluating its Trap &amp; Target platform. The study showed that the platform&#8217;s formulation achieved targeted deposition in the upper regions of the nasal cavity.
Price Action: PLRZ surged 52.47% to close at $1.04 on July 16, according to <a href="https://www.benzinga.com/quote/plrz">Benzinga Pro</a> data.
Benzinga&#8217;s Edge Stock Rankings indicate Polyrizon stocks have negative trends across all time frames. Know how the stock fares on <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">other parameters here</a>.
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="463" height="110" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024751/Screenshot-2025-07-16-121735.png" alt="" class="wp-image-987194" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024751/Screenshot-2025-07-16-121735.png 463w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024751/Screenshot-2025-07-16-121735-300x71.png 300w" sizes="(max-width: 463px) 100vw, 463px" /></a></figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/equities/25/07/46435021/nuwellis-soars-31-25-in-after-hours-trading-whats-behind-the-surge">Nuwellis Soars 31.25% In After-Hours Trading — What&#8217;s Behind The Surge?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Shutterstock/iQoncept

Biotech

Equities

News

Events

Market-Moving Exclusives

Signals

Pre-Market Outlook

Markets

General

PLRZ

Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved

President&nbsp;Donald Trump&nbsp;said Tuesday he has secured the commitment of House Republicans to vote in favor of the GENIUS Act after procedural failures halted its progress earlier in the day.
What Happened:&nbsp;In a Truth Social <a href="https://truthsocial.com/@realDonaldTrump/posts/114860136006223294">post</a>, Trump said that he had secured the support of 11 out of the 12 necessary Congress members&nbsp;to pass the GENIUS Act, also known as the stablecoin bill. The decision was reached during a meeting in the Oval Office, with&nbsp;Speaker of the House Mike Johnson&nbsp;(R-La.) participating via telephone. 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="737" height="447" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16030932/image-189.png" alt="" class="wp-image-987243" style="width:470px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16030932/image-189.png 737w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16030932/image-189-300x182.png 300w" sizes="(max-width: 737px) 100vw, 737px" /></figure>
&#8220;After a short discussion, they have all agreed to vote tomorrow morning in favor of the Rule,&#8221; Trump said. &#8220;I want to thank the Congressmen/women for their quick and positive response.&#8221;
Republicans, including Rep.&nbsp;Marjorie Taylor Greene&nbsp;(R-Ga.), had opposed the Act earlier due to a lack of a clause prohibiting Central Bank Digital Currency and the Speaker&#8217;s refusal to consider amendments.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I just voted NO on the Rule for the GENIUS Act because it does not include a ban on Central Bank Digital Currency and because Speaker Johnson did not allow us to submit amendments to the GENIUS Act. Americans do not want a government-controlled Central Bank Digital Currency.… <a href="https://t.co/NnkeIOH0dE">pic.twitter.com/NnkeIOH0dE</a>
&mdash; Rep. Marjorie Taylor Greene&#x1f1fa;&#x1f1f8; (@RepMTG) <a href="https://twitter.com/RepMTG/status/1945195703292092555?ref_src=twsrc%5Etfw">July 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The GENIUS Act has received a lot of attention, especially since it <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45989307/senate-passes-genius-act-coinbases-brian-armstrong-calls-it-big-milestone-scott-bessent-says-passage-could-drive-stablecoins-into-a-3-7-trillion-market">passed the Senate</a> last month. 
Earlier, Trump&nbsp;wished everyone a&nbsp;&#8220;Happy Crypto Week"&nbsp;and urged all Republicans to support the GENIUS Act to make the U.S. the undisputed leader in digital assets. However, the <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46433854/trumps-happy-crypto-week-gets-off-to-rocky-start-as-house-suspends-votes-on-key-bills">procedural vote needed</a> to advance key cryptocurrency bills failed, resulting in the suspension of further votes.
Photo courtesy: Maxim Elramsisy / Shutterstock.com
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46392541/how-donald-trumps-big-beautiful-bill-was-a-big-beautiful-boost-for-bitcoin" target="_blank" rel="noreferrer noopener">How Donald Trump's ‘Big Beautiful Bill' Was A ‘Big Beautiful Boost' For Bitcoin</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trump Says 11 Of 12 Republicans Needed Now Support Stablecoin Bill After Earlier Setback — They've All Agreed To Vote In Favor

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it&#8217;s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/NVO">NVO stock here</a>.
What Happened: Explaining that the pharmaceutical companies as a whole are &#8220;out of favor&#8221; for tariffs, Field <a href="https://www.cnbc.com/video/2025/07/14/barclays-the-pharma-sector-is-very-out-of-favor-for-tariffs.html">told</a> CNBC that it was hard to single out a company that could be the most affected by the levies.
&#8220;It&#8217;s really difficult to say because they have really complex supply chains and companies like to keep it under the wraps,&#8221; she said, adding that &#8220;Novo Nordisk has been called out just because we know a lot of active pharmaceutical ingredients for Wegovy are manufactured in Denmark, so that&#8217;s just one that investors have highlighted.&#8221;
She adds, &#8220;But that could also just be because we have a more concrete idea of how their drug flows. But for the most part, this sector is just very out of favor for tariffs.&#8221;
Talking about the European pharma companies that were planning to invest in the U.S., Field mentioned Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Roche Holdings AG (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTCQX">RHHBY</a>), and AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
&#8220;We have seen from a number of European companies very significant announcements about manufacturing investments in the United States. We have seen that from Novartis, Roche, and we also know that the companies are working with the administration on this &#8216;Most Favored Nation&#8217; (MFN) drug pricing policy,&#8221; she said.
She also added that AstraZeneca is likely considering changing its registration to the U.S. &#8220;All of the companies based in Europe are emphasizing that they are very committed to the U.S. and manufacturing in the U.S.&#8221;
According to Field, this is all connected in some way. &#8220;It could be a combination of tariffs and drug pricing that the industry and administration can strike a deal that is favorable to both parties,&#8221; Field explained.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46400448/dan-ives-bets-on-cybersecurity-as-biggest-subsector-in-tech-for-2025-expects-strong-q2-earnings-from-crowdstrike-zscaler-palo-alto-check-point">Dan Ives Bets On Cybersecurity As &#8216;Biggest Subsector&#8217; In Tech For 2025; Expects Strong Q2 Earnings From CrowdStrike, Zscaler, Palo Alto, Check Point</a>
Why It Matters: Barclays has also <a href="https://www.benzinga.com/markets/equities/25/07/46364024/trump-threatens-200-pharma-tariffs-but-analyst-says-this-stock-is-immune-and-expected-to-benefit-from-levies">cautioned that a 200% pharma tariff</a> would &#8220;inflate production costs, compress profit margins, and risk supply chain disruptions." 
&#8220;We are waiting for the results of the Section 232 investigation from the Commerce Ministry, which is supposed to come by the end of the month. Prior to Trump saying that he was going to announce 200%, I think most have been expecting 25%; however, the industry&#8217;s response is that tariffs will be negative for patients, as it could result in drug shortages,&#8221; Feild said.
These are some pharma ETFs that could be impacted as the long-awaited industry-wide tariffs would be announced &#8220;very soon,&#8221; according to Trump.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>0.45%</td>
<td>-6.90%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>1.01%</td>
<td>-3.91%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-1.22%</td>
<td>-3.19%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-1.95%</td>
<td>-1.55%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>29.34%</td>
<td>33.78%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-3.88%</td>
<td>-8.36%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-18.59%</td>
<td>-24.16%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended mixed on Tuesday. The SPY was down 0.43% at $622.14, while the QQQ advanced 0.092% to $556.72, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
On Wednesday, the futures of the S&amp;P 500, Dow Jones, and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surged-nearly-50-in-2025">Stanley Druckenmiller&#8217;s Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Photo courtesy: JHVEPhoto / Shutterstock.com

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

RHHBY

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

ANTA

GLXY

Backed By Galaxy Digital And Antalpha, Function Launches FBTC With $1.5B In TVL To Transform Bitcoin Into A Productive Financial Asset

IPOs

MGRT

Reported Earlier, Mega Fortune Prices $15M Initial Public Offering Of 3.75M Common Shares At $4.00 Per Share

ZJYL

Reported Earlier, Jin Medical Launches Production At Plant No. 3 In Chuzhou To Accelerate Global Delivery Of High-Precision Rehabilitation Devices

Fiscal Year 2025 Financial Summary
<ul>
<li>Net revenues were $25.4 million in fiscal year 2025, compared to $32.2 million in fiscal year 2024.</li>
<li>Gross profit was $10.5 million in fiscal year 2025, compared to $13.1 million in fiscal year 2024.</li>
<li>Gross margin was 41.1% in fiscal year 2025, increased from 40.7% in fiscal year 2024.</li>
<li>Net Loss was $5.3 million in fiscal year 2025, compared to net income of $1.9 million in fiscal year 2024.</li>
<li>Basic and diluted losses per share were $1.10 in fiscal year 2025, compared to basic and diluted earnings per share of $0.43 in fiscal year 2024.</li>
</ul>

Earnings

FLYE

Reported Earlier, Fly-E Group FY2025 EPS $(1.10) Down From $0.43 YoY, Revenue $25.427M Down From $32.205M YoY

Elon Musk&#8216;s strategy to leverage resources across his business empire, including&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), SpaceX, and xAI, has sparked investor concerns, particularly after a recent controversy involving chatbot Grok.
What Happened: Musk is promoting a &#8216;Muskonomy&#8217; strategy that would allow investors to invest in his various businesses, which include SpaceX, X, xAI, and The Boring Company, <a href="https://www.businessinsider.com/elon-musk-north-star-ai-tesla-xai-spacex-investments-2025-7">reported</a> Business Insider. He has even promised to prioritize &#8220;longtime shareholders&#8221; if any of his companies go public. This strategy could potentially help Tesla meet its AI demands for autonomous driving by leveraging resources across Musk&#8217;s other companies.
Check out the current price of&nbsp;<a href="https://benzinga.com/quote/aapl" target="_blank" rel="noreferrer noopener">TSLA stock here</a>.
However, this strategy carries notable risks. For example, Grok's recent controversy over anti-Semitic content on X has raised alarms about incorporating the chatbot into Tesla's electric vehicles. Additionally, Musk's move last year to redirect a $500 million shipment of Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips—originally meant for Tesla—to X and xAI triggered concern among investors. Musk defended the move, saying it was beneficial for Tesla as the company lacked the infrastructure to utilize the chips at the time.
Analyst Gadjo Sevilla from EMARKETER, expressed concern about Musk&#8217;s strategy of &#8220;cannibalizing one business to prop&nbsp;up another one could take its toll.&#8221; This could potentially delay innovation at Tesla, warned the analyst.
Meanwhile, Garrett Nelson, senior VP and equity analyst at CFRA Research, pointed out that other companies usually conduct the interplay under &#8220;one corporate umbrella.&#8221; However, with Musk, &#8220;the relationship and interplay between his private companies and a public company (Tesla)&#8221; is the key distinguishing factor.
See Also:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/07/46429234/bitcoin-xrp-dogecoin-dip-but-ethereum-outperforms-after-inflation-report" target="_blank" rel="noreferrer noopener">Bitcoin, XRP, Dogecoin Dip But Ethereum Outperforms After Inflation Report &#8211; Benzinga</a>
Why It Matters: Musk&#8217;s &#8216;Muskonomy&#8217; strategy comes at a crucial time for Tesla, which is currently facing an <a href="https://www.benzinga.com/markets/tech/25/07/46392190/tesla-identity-crisis-musks-xai-vote-could-rewrite-the-ev-makers-dna">identity crisis</a>. Musk recently announced that Tesla shareholders would vote on a potential investment in his AI venture, xAI, raising questions about whether Tesla is evolving into an AI-fueled tech conglomerate. 
While veteran investor Gary Black suggested that a shareholder vote would be the fairest way to decide on a potential merger between Tesla and xAI, some are questioning Musk&#8217;s plans to sell xAI.
Musk has been vocal about his desire for Tesla to invest in xAI, but has left the final decision to the shareholders. Despite the potential risks, some analysts believe that xAI is worth the bet, as it could significantly benefit Tesla&#8217;s AI ambitions.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="773" height="120" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024150/image-187.png" alt="" class="wp-image-987176" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024150/image-187.png 773w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024150/image-187-300x47.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16024150/image-187-768x119.png 768w" sizes="(max-width: 773px) 100vw, 773px" /></figure>
Benzinga's Edge Rankings place Tesla in the 50th percentile for quality and the 91st percentile for growth, reflecting mixed performance. Check the detailed report <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a>.&nbsp;
READ MORE: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46434613/elon-musks-tesla-could-face-stricter-oversight-as-trumps-nhtsa-pick-targets-autonomous-driving-cannot-sit-back">Elon Musk&#8217;s Tesla Could Face Stricter Oversight As Trump&#8217;s NHTSA Pick Targets Autonomous Driving: &#8216;Cannot Sit Back&#8217; </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

NVDA

TSLA

Elon Musk's 'Muskonomy' Strategy Could Take A 'Toll' On Tesla, Potentially Delaying Innovation, Warn Experts

today announced the pricing of a public offering of an aggregate of 9,090,909 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase 9,090,909 shares of its common stock and Series B warrants to purchase 9,090,909 shares of its common stock, at a combined public offering price of $0.55 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. Each of the Series A warrants and the Series B warrants will have an exercise price of $0.55 per share and will be exercisable immediately upon issuance.&nbsp;

SLNH

Reported Earlier, Soluna Holdings Prices $5M Common Stock And Warrant Offering At $0.55 Per Unit

Reported Earlier, LiveOne Launches Proposed Public Offering Of Common Stock

<ul>
<li>Expected to Generate ~$470 million in Net Proceeds, Reflecting Strong Equity Appreciation</li>
<li>Newmont Remains on Track to Deliver on its 2025 Guidance and Capital Allocation Priorities</li>
</ul>

Reported Earlier, Newmont Monetizes Equity From Greatland And Discovery Stakes With ~230% And ~200% Returns, Generating ~$470M In Net Proceeds

Reported Earlier, AECOM Prices $1.2B Of Senior Unsecured Notes Due 2033 With 6.0% Coupon To Support Tender Offer And Redemption Of 2027 Notes

TTGT

Reported Earlier, TechTarget Restores Compliance With Nasdaq Listing Rules Following July 14 Filing Of Q1 2025 Form 10-Q

HBAN

VBTX

Reported Earlier, Veritex Holdings Reschedules Q2 2025 Earnings Release To July 18 And Cancels Conference Call Following Acquisition Agreement With Huntington Bancshares

Vlad Tenev, the CEO of Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), is defending his company&#8217;s bold move to give retail investors exposure to shares in high-profile private companies such as SpaceX and OpenAI, without seeking their permission. 
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/HOOD" target="_blank" rel="noreferrer noopener">HOOD stock here.</a>
What Happened: Speaking on the 20VC podcast on Tuesday, Tenev revealed that Robinhood's new tokenization platform offers access to private market exposure for retail investors through structured instruments, effectively bypassing the need for companies to opt in.
Tenev says, &#8220;It's important for the tokenization mechanism to work without the opt-in of the companies that are being tokenized,&#8221; and he believes that&#8217;s the actual innovation that his company&#8217;s been able to drive. 
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46425416/jamie-dimon-admits-big-banks-are-behind-in-the-stablecoin-race">Jamie Dimon Admits Big Banks Are Behind In The Stablecoin Race</a>
He notes that the initiative has received pushback from a few of the companies involved. &#8220;They were a little bit upset by this,&#8221; he says, specifically referencing OpenAI, the company behind ChatGPT. Tenev says the company issued a cautionary statement in response to this, which he describes as &#8220;a little bit gratuitous.&#8221;
Tenev, nonetheless, remains committed to Robinhood&#8217;s broader mission of democratizing finance. &#8220;Everyone likes tokenization in principle, right? But it's not really as attractive when it's being done to you,&#8221; he says. 
&#8220;Some of the most important companies of our time have not been accessible to retail, and I think that's a huge problem,&#8221; Tenev says.
Neither SpaceX nor OpenAI immediately responded to Benzinga&#8217;s requests for a comment on this matter. This story will be updated as soon as we hear back.
Why It Matters: According to Matt Hougan, the chief investment officer at Bitwise Asset Management, tokenization represents <a href="https://www.benzinga.com/markets/25/07/46420155/the-tokenization-market-has-a-4-000x-growth-potential-according-bitwise-heres-the-cleanest-way-to-in">a 4,000x opportunity</a>, with stocks and bonds alone worth over $257 trillion combined.
BlackRock CEO, Larry Fink, said in his shareholders&#8217; letter recently that &#8220;Every stock, every bond, every fund-every asset-can be tokenized,&#8221; highlighting the enormity of this market.
Price Action: Shares of Robinhood touched an <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46376607/robinhood-surges-to-all-time-highs-this-week-after-crypto-expansion-despite-regulatory-scrutiny">all-time high</a> last week when the company launched the tokenized versions of 200 publicly listed equities across Europe. On Tuesday, the stock was down 0.42%, trading at $99.54, and is up 0.25% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="146" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16022416/Screenshot-2025-07-16-at-11.54.04-AM-1024x146.png" alt="" class="wp-image-987137" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16022416/Screenshot-2025-07-16-at-11.54.04-AM-1024x146.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16022416/Screenshot-2025-07-16-at-11.54.04-AM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16022416/Screenshot-2025-07-16-at-11.54.04-AM-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16022416/Screenshot-2025-07-16-at-11.54.04-AM.png 1528w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Robinhood scores high on Momentum and Growth in Benzinga&#8217;s Edge Stock Rankings, and has a favorable price trend in the short, medium and long terms. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights into the stock, its peers and competitors. 
Photo: Bangla press / Shutterstock.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46419665/cramers-parc-playbook-robinhoods-breakout-potential-outshines-the-meme-stock-pack">Cramer&#8217;s PARC Playbook: Robinhood&#8217;s Breakout Potential Outshines The Meme Stock Pack</a></li>
</ul>

HOOD

Robinhood CEO Vlad Tenev Defends Tokenizing Elon Musk's SpaceX, Sam Altman's OpenAI: 'They Were A Little Bit Upset…'

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has signed a $500 million deal with MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), a Pentagon-backed company, to secure a supply of rare earth magnets. This agreement is a strategic step to ensure a consistent supply of critical components and reduce reliance on China.
What Happened: This deal, announced on Tuesday, is one of the first U.S. supply agreements signed by a tech company following China&#8217;s export restrictions earlier this year, reported Reuters.
&#8220;Rare earth materials are essential for making advanced technology, and this partnership will help strengthen the supply of these vital materials here in the United States,&#8221; said Apple CEO Tim Cook.
The deal includes a $200 million prepayment from Apple and will support production at MP's upcoming facility in Fort Worth, Texas, using recycled materials from its site in Mountain Pass, California.
See Also: <a href="https://benzinga.com/crypto/cryptocurrency/25/07/46394828/bitcoin-eth-xrp-solana-are-in-for-a-long-and-exhausting-bull-market-bernstein-predicts" target="_blank" rel="noopener">Bitcoin, ETH, XRP, Solana Are In For A &#8216;Long And Exhausting Bull Market,&#8217; Bernstein Predicts &#8211; Benzinga</a>
Apple did not disclose which products would use the magnets, but MP said the supply would support hundreds of millions of devices.
The agreement is part of Apple's larger $500 billion, four-year investment commitment to the U.S. economy. Analysts said Apple saw the expense of supporting U.S. magnet production as minor compared to the long-term risk of potentially losing access to these critical components altogether.
Why It Matters: The deal between Apple and MP Materials comes at a time when the global supply chain for rare earth materials is under strain.
China, the largest producer of rare earths, <a href="https://www.benzinga.com/markets/tech/25/06/45826735/china-grants-temporary-rare-earth-licenses-to-us-automakers-suppliers">halted exports in March</a> following a trade dispute with the U.S. This move led to increased demand for non-Chinese supply, prompting companies like Apple to seek alternative sources.
Earlier this month, economist Craig Shapiro warned that the U.S. faces a <a href="https://www.benzinga.com/markets/equities/25/07/46214341/china-showed-its-death-grip-on-rare-earths-during-trump-tariff-war-but-craig-shapiro-says-this-2-billion-plan-will-secure-us-supply-heres-how">serious supply chain risk</a> due to its dependence on China for rare earth magnets—essential for EVs, AI, and defense technologies. However, he believed the issue is fixable with a relatively modest investment of $1–2 billion.
His proposed strategy includes accelerating domestic projects using the Defense Production Act, building magnet plants, forming global alliances, and stockpiling materials.
Shapiro emphasized speed and access over ideology, advising investors to focus on scarcity and consider stocks like MP Materials, Lynas, and other rare earth and strategic metals plays.
Price Action: Apple shares rose 0.23% to close at $209.11 on Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/news/topics/25/07/46425911/peter-thiel-backed-startup-that-sends-drones-in-ukraine-eyes-10000-units-monthly-absolutely-required-" target="_blank" rel="noopener">Peter Thiel-Backed Startup That Sends Drones In Ukraine Eyes 10,000 Units Monthly: &#8216;Absolutely Required&#8217; To Win Future Conflicts, CEO Warns</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: jamesteohart / Shutterstock.com

Tech

AAPL

Apple Strikes $500 Million Deal With MP Materials To Reduce China Reliance On Critical Magnets

Larry Ellison, Oracle Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) co-founder and chairman, has <a href="https://www.benzinga.com/markets/tech/25/06/45919978/larry-ellison-overtakes-jeff-bezos-mark-zuckerberg-to-become-worlds-second-richest-amid-oracles-watershed-moment">once again</a> overtaken Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg to become the world's second-richest person. This is despite them both having $251 billion net worth.
What Happened: According to Bloomberg's Billionaire <a href="https://www.bloomberg.com/billionaires/">Index</a>, Ellison and Zuckerberg are tied at $251 billion, but because Ellison has gained $59 billion this year while the Meta CEO is up $43.4 billion, the Oracle co-founder might have placed above.
This ranks him just after Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and SpaceX CEO Elon Musk, who remains the world's richest person at $358 billion.
Others in the top five wealthiest individuals list are Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos and former Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) CEO Steve Ballmer, with net worths of $247 billion and $174 billion, respectively.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46434347/nvidia-says-washington-gets-it-after-trumps-ai-czar-david-sacks-says-us-has-to-outcompete-global-rivals">Nvidia Says &#8216;Washington Gets It&#8217; After Trump&#8217;s AI Czar David Sacks Says US Has To &#8216;Outcompete&#8217; Global Rivals</a>
Why It&#8217;s Important: Ellison's wealth, more than 80% of which is tied to Oracle stock and options, soared as Oracle shares climbed 47.27% in the last six months, <a href="https://www.bloomberg.com/news/articles/2025-07-15/ellison-overtakes-zuckerberg-as-world-s-second-richest-person">reported </a>Bloomberg.
The rally followed news on Tuesday that the U.S. government would <a href="https://www.benzinga.com/markets/tech/25/07/46409079/nvidia-growth-estimates-get-10-boost-as-us-lifts-china-chip-export-curbs-gene-munster-predicts-30-35-growth-for-2026">ease export restrictions</a>, allowing chipmakers like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) to resume selling some semiconductors to China.
Oracle, which relies on high-end chips for its cloud and AI infrastructure, was among the top beneficiaries of the policy shift with a gain of 2.48% during Tuesday's regular trading session, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has also inked <a href="https://www.benzinga.com/25/03/44188361/nvidia-powers-openai-and-oracles-100-billion-stargate-first-ai-data-center-set-to-launch-in-texas">multibillion-dollar cloud deals</a> and ramped up partnerships with firms including OpenAI and SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) as part of its Stargate initiative.
Oracle's stock has also nearly tripled since OpenAI released ChatGPT in November 2022, the report said.
According to Benzinga's Edge Stock Rankings, Oracle is demonstrating strong positive momentum in the short, medium and long term. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound'">Additional performance insights are available here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound'"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023211/Screenshot-2025-07-16-at-12.00.15%E2%80%AFPM.png" alt="" class="wp-image-987149" /></a></figure>
Photo courtesy: drserg / Shutterstock.com
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare" target="_blank" rel="noreferrer noopener">Get Ready For 800 Hours Of Blackouts, Trump's DOE Warns</a>&nbsp;</li>
</ul>

Media

AMZN

MSFT

ORCL

SFTBF

SFTBY

Larry Ellison Surges Past Mark Zuckerberg To Become World's Second-Richest Person As Oracle's AI Deals With OpenAI, US Government Drive Massive Stock Surge

Mattel and GCDS Elevate Polly Pocket With Special Edition Capsule Collection and Italian-Inspired Compact For Mattel Creations

Mastercard Introduces New Suite Of Premium Experiences For Cardholders Globally With Launch Of World Legend Mastercard And The Mastercard Collection

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the &#8220;Greed&#8221; zone on Tuesday.
U.S. stocks settled mostly lower on Tuesday, with the Dow Jones index falling more than 400 points during the session following a mixed bag of earnings from big banks. The Nasdaq 100 surged to fresh record highs on Tuesday, breaking above the 23,000 mark as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and other chipmakers powered a sharp rally.
Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) reported better-than-expected second-quarter adjusted EPS results. JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported upbeat second-quarter earnings.
On the economic data front, U.S. inflation accelerated for a second straight month. The headline consumer price index rose 2.7% year-over-year in June, the highest since February and in line with expectations. However, core inflation, which strips out food and energy, came in slightly below forecasts at 2.9%, versus 3.0% expected.
Most sectors on the S&amp;P 500 closed on a negative note, with financial, materials and health care stocks recording the biggest losses on Tuesday. However, information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by 436 points to 44,023.29 on Tuesday. The S&amp;P 500 fell 0.40% to 6,243.76, while the Nasdaq Composite gained 0.18% to 20,677.80 during Tuesday's session.
Investors are awaiting earnings results from Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 73.6, the index moved to the &#8220;Greed&#8221; zone on Tuesday, versus a prior reading of 76.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46415122/top-2-tech-telecom-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Tech &amp; Telecom Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Tumbles Over 400 Points As Inflation Rises Faster Than Expected: Fear Index Moves To 'Greed' Zone

Press Releases

Solid Biosciences to Participate at Upcoming Investor Conferences

Health Care

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Comments

Solid Biosciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL